28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04298372 (ClinicalTrials.gov) | February 20, 2019 | 3/12/2019 | Frontline Lenalidomide for AL Amyloidosis Involving Myocardium | Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide | Amyloidosis Cardiac | Drug: Lenalidomide 25mg | Seoul National University Hospital | NULL | Recruiting | 19 Years | 99 Years | All | 30 | Phase 3 | Korea, Republic of |
| 2 | NCT03252600 (ClinicalTrials.gov) | August 25, 2017 | 24/7/2017 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis | Recurrent Primary Amyloidosis | Drug: Cyclophosphamide;Drug: Dexamethasone;Biological: Elotuzumab;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Pharmacological Study | Barbara Ann Karmanos Cancer Institute | National Cancer Institute (NCI);Bristol-Myers Squibb;Multiple Myeloma Research Consortium | Active, not recruiting | 18 Years | N/A | All | 53 | Phase 2 | United States |
| 3 | NCT01194791 (ClinicalTrials.gov) | October 2010 | 26/7/2010 | Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed | A Multicentric, Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed, Not Candidates for Hematopoietic Stem Cell Transplantation | Primary Systemic Amyloidosis | Drug: Lenalidomide;Drug: Cyclophosphamide;Drug: Dexamethasone | PETHEMA Foundation | NULL | Completed | 18 Years | N/A | All | 30 | Phase 2 | Spain |
| 4 | NCT00890552 (ClinicalTrials.gov) | April 2009 | 28/4/2009 | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | Leukemia;Amyloidosis | Drug: Lenalidomide;Drug: Melphalan;Drug: Dexamethasone | Stanford University | Celgene Corporation | Completed | 18 Years | N/A | All | 25 | N/A | United States |
| 5 | NCT00883623 (ClinicalTrials.gov) | April 2009 | 15/4/2009 | A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis | A Prospective Single Center Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With AL Amyloidosis | Primary Amyloidosis | Drug: Lenalidomide | Heidelberg University | Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH | Completed | 18 Years | 74 Years | Both | 50 | Phase 2 | Germany |
| 6 | EUCTR2008-001405-41-DE (EUCTR) | 24/10/2008 | 28/08/2008 | A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX | A prospective trial of treatment with Lenalidomide-Melphalan-Dexamethason (L-Mel-Dex) in untreated patients with AL amyloidosis (LEOMEX) - LEOMEX | AL amyloidosis | Trade Name: Revlimid Other descriptive name: Lenalidomide Trade Name: Alkeran Product Code: L01AA03 Other descriptive name: melphalan Trade Name: Fortecortin Other descriptive name: dexamethasone | GMIHO mbH | NULL | Not Recruiting | Female: yes Male: yes | Germany | ||||
| 7 | NCT00679367 (ClinicalTrials.gov) | May 2008 | 14/5/2008 | Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | A Phase II Trial of MRD (Melphalan, Lenalidomide and Dexamethasone) for Patients With AL Amyloidosis | Multiple Myeloma | Drug: dexamethasone;Drug: lenalidomide;Drug: melphalan | Boston Medical Center | NULL | Completed | 18 Years | N/A | All | 16 | Phase 2 | United States |
| 8 | EUCTR2007-006037-13-IT (EUCTR) | 21/02/2008 | 10/12/2007 | An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND | An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - ND | amyloidosis AL MedDRA version: 6.1;Level: PT;Classification code 10002022 | Trade Name: Revlimid INN or Proposed INN: Cyclophosphamide INN or Proposed INN: Dexamethasone | OSPEDALE POLICLINICO S. MATTEO | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy | |||
| 9 | NCT00607581 (ClinicalTrials.gov) | February 2008 | 22/1/2008 | Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis | Amyloidosis | Drug: cyclophosphamide;Drug: lenalidomide;Drug: dexamethasone | IRCCS Policlinico S. Matteo | Celgene Corporation | Completed | 18 Years | N/A | Both | 21 | Phase 2 | Italy |
| 10 | NCT00981708 (ClinicalTrials.gov) | February 2008 | 19/9/2009 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | A Phase I/II Trial of Lenalidomide Combined With Cyclophosphamide and Intermediate Dose Dexamethasone in Patients With Primary (AL) Systemic Amyloidosis | Amyloidosis | Drug: Lenalidomide, Dexamethasone and Cyclophosphamide | University of Athens | Hellenic Cooperative Oncology Group | Completed | 18 Years | N/A | All | 37 | Phase 1/Phase 2 | Greece |
| 11 | NCT00564889 (ClinicalTrials.gov) | December 2007 | 28/11/2007 | Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | A Phase II Trial of Lenalidomide (Revlimid®), Cyclophosphamide and Dexamethasone in Patients With Primary Systemic Amyloidosis | Multiple Myeloma and Plasma Cell Neoplasm | Drug: cyclophosphamide;Drug: dexamethasone;Drug: lenalidomide | Mayo Clinic | National Cancer Institute (NCI) | Completed | 18 Years | N/A | All | 35 | Phase 2 | United States |
| 12 | EUCTR2006-007082-36-GR (EUCTR) | 16/10/2007 | 18/07/2007 | A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis | A Phase I/II trial of lenalidomide combined with cyclophosphamide and intermediate dose dexamethasone in patients with primary (AL) systemic amyloidosis - CDR in amyloidosis | Primary (AL) amyloidosis in untreated patients or patientsw who have failed prior treatments | Trade Name: REVLIMID Trade Name: Endoxan Trade Name: Dexamethasone Trade Name: REVLIMID INN or Proposed INN: Lenalidomide INN or Proposed INN: Deaxamethasone INN or Proposed INN: cyclophosphamide | Hellenic Oncology Cooperative Group | NULL | Not Recruiting | Female: yes Male: yes | 55 | Phase 1/2 | Greece | ||
| 13 | NCT00166413 (ClinicalTrials.gov) | April 2005 | 12/9/2005 | Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis | A Phase II Trial of CC-5013 in Patients With Primary Systemic Amyloidosis | Amyloidosis | Drug: CC-5013 | Mayo Clinic | NULL | Completed | 18 Years | N/A | Both | 38 | Phase 2 | United States |
| 14 | NCT00091260 (ClinicalTrials.gov) | January 2004 | 7/9/2004 | CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | A Phase II Trial of the Immunomodulatory Drug CC-5013 for Patients With AL Amyloidosis | Multiple Myeloma | Drug: dexamethasone;Drug: lenalidomide | Vaishali Sanchorawala | Celgene Corporation | Completed | 18 Years | N/A | All | 82 | Phase 2 | United States |